Aequus Pharmaceuticals Inc. (AQSZF)
- Previous Close
0.0094 - Open
0.0094 - Bid --
- Ask --
- Day's Range
0.0094 - 0.0094 - 52 Week Range
0.0079 - 0.0400 - Volume
28,897 - Avg. Volume
29,409 - Market Cap (intraday)
1.444M - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Apr 29, 2024 - May 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.
www.aequuspharma.ca12
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AQSZF
Performance Overview: AQSZF
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AQSZF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AQSZF
Valuation Measures
Market Cap
1.44M
Enterprise Value
4.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.94
Price/Book (mrq)
--
Enterprise Value/Revenue
7.32
Enterprise Value/EBITDA
-1.43
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-83.91%
Return on Equity (ttm)
--
Revenue (ttm)
587.09k
Net Income Avi to Common (ttm)
-3.27M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
112.02k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-943.17k